BG62489B1 - Приложение на диметилбензофурани като 5-нт3 антагонисти - Google Patents

Приложение на диметилбензофурани като 5-нт3 антагонисти Download PDF

Info

Publication number
BG62489B1
BG62489B1 BG99593A BG9959395A BG62489B1 BG 62489 B1 BG62489 B1 BG 62489B1 BG 99593 A BG99593 A BG 99593A BG 9959395 A BG9959395 A BG 9959395A BG 62489 B1 BG62489 B1 BG 62489B1
Authority
BG
Bulgaria
Prior art keywords
formula
enantiomer
methoxy
amino
cis
Prior art date
Application number
BG99593A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG99593A (en
Inventor
Georges H. Van Daele
Jean-Paul R. Bosmans
Willy J. Van Laerhoven
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG99593A publication Critical patent/BG99593A/xx
Publication of BG62489B1 publication Critical patent/BG62489B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG99593A 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти BG62489B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (2)

Publication Number Publication Date
BG99593A BG99593A (en) 1995-12-29
BG62489B1 true BG62489B1 (bg) 1999-12-30

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99593A BG62489B1 (bg) 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти

Country Status (31)

Country Link
US (2) US5674868A (fi)
EP (1) EP0669919B1 (fi)
JP (1) JP2830952B2 (fi)
KR (1) KR0166661B1 (fi)
AT (1) ATE176232T1 (fi)
AU (1) AU680640B2 (fi)
BG (1) BG62489B1 (fi)
BR (1) BR9307477A (fi)
CA (1) CA2149044C (fi)
CZ (1) CZ287262B6 (fi)
DE (1) DE69323322T2 (fi)
DK (1) DK0669919T3 (fi)
ES (1) ES2129615T3 (fi)
FI (1) FI952458A (fi)
GR (1) GR3029831T3 (fi)
HU (2) HUT72740A (fi)
IL (3) IL119273A0 (fi)
LV (1) LV10956B (fi)
MX (1) MX9307257A (fi)
NO (2) NO307690B1 (fi)
NZ (1) NZ257854A (fi)
OA (1) OA10158A (fi)
PL (1) PL176051B1 (fi)
RO (1) RO115160B1 (fi)
RU (1) RU2116072C1 (fi)
SG (1) SG47488A1 (fi)
SK (1) SK282378B6 (fi)
TW (1) TW294595B (fi)
UA (1) UA49792C2 (fi)
WO (1) WO1994012494A1 (fi)
ZA (1) ZA938676B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US6235745B1 (en) 1997-04-18 2001-05-22 Janssen Pharmaceutica N.V. Use of 5HT3, antagonists for promoting intestinal lavage
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
BRPI0416817A (pt) 2003-11-20 2007-03-06 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase
CA2569824C (en) 2004-06-30 2013-03-19 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006003148A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
EP1771422B1 (en) 2004-06-30 2011-02-16 Janssen Pharmaceutica NV Quinazolinone derivatives as parp inhibitors
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
EP2260026B1 (en) 2008-03-27 2011-06-22 Janssen Pharmaceutica, N.V. Quinazolinone derivatives as tubulin polymerization inhibitors
EP2271626B1 (en) 2008-03-27 2014-11-26 Janssen Pharmaceutica, N.V. Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
IL119273A0 (en) 1996-12-05
RO115160B1 (ro) 1999-11-30
RU95113434A (ru) 1997-03-10
HUT72740A (en) 1996-05-28
MX9307257A (es) 1994-05-31
ATE176232T1 (de) 1999-02-15
RU2116072C1 (ru) 1998-07-27
LV10956B (en) 1996-10-20
NO995762D0 (no) 1999-11-24
BR9307477A (pt) 1999-06-29
IL119273A (en) 2000-07-16
FI952458A0 (fi) 1995-05-19
CZ125895A3 (en) 1995-10-18
LV10956A (lv) 1995-12-20
EP0669919B1 (en) 1999-01-27
DE69323322T2 (de) 1999-09-09
HU211546A9 (en) 1995-12-28
FI952458A (fi) 1995-05-19
BG99593A (en) 1995-12-29
JPH08505840A (ja) 1996-06-25
SG47488A1 (en) 1998-04-17
PL309045A1 (en) 1995-09-18
IL107654A (en) 1998-01-04
KR0166661B1 (ko) 1999-01-15
UA49792C2 (uk) 2002-10-15
NO308530B1 (no) 2000-09-25
SK67595A3 (en) 1995-11-08
NO951980L (no) 1995-05-19
SK282378B6 (sk) 2002-01-07
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
CA2149044C (en) 2007-04-03
PL176051B1 (pl) 1999-03-31
IL107654A0 (en) 1994-02-27
NO951980D0 (no) 1995-05-19
ES2129615T3 (es) 1999-06-16
OA10158A (en) 1996-12-18
CZ287262B6 (en) 2000-10-11
AU5465994A (en) 1994-06-22
JP2830952B2 (ja) 1998-12-02
TW294595B (fi) 1997-01-01
CA2149044A1 (en) 1994-06-09
HU9501476D0 (en) 1995-07-28
WO1994012494A1 (en) 1994-06-09
DE69323322D1 (de) 1999-03-11
US5674868A (en) 1997-10-07
NO307690B1 (no) 2000-05-15
DK0669919T3 (da) 1999-09-13
US5863923A (en) 1999-01-26
EP0669919A1 (en) 1995-09-06
NZ257854A (en) 1997-04-24
GR3029831T3 (en) 1999-06-30
AU680640B2 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
JP3940359B2 (ja) 化合物
EP1339406B1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
BG62489B1 (bg) Приложение на диметилбензофурани като 5-нт3 антагонисти
AU2001295723A1 (en) Chemical compounds
DE60127434T2 (de) Benzoxazinonderivative, deren herstellung und verwendung
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
WO1992022527A2 (en) 3-substituted pyrrolidine derivatives as calcium channel antagonists
HU204254B (en) Process for producing pharmaceutical compositions against diarrohe containing 4-(aroyl-amino)-piperidine-butaminide derivatives and for producing the new 4-(aroyl-amino)-piperidine derivatives
US20110230485A1 (en) 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors
EP2393800B1 (en) Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
JP2001512491A (ja) 1−(イソキノリン−1−イル)−4−(1−フェニメチル)ピペラジン;ドーパミン受容体サブタイプ特異的リガンド
KR19980701921A (ko) 혈관 수축성 치환된 2,3-디하이드로-1,4-디옥시노피리딘
WO2007009758A2 (en) 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist